Clinical Trials Logo

Hematologic Malignancies clinical trials

View clinical trials related to Hematologic Malignancies.

Filter by:

NCT ID: NCT05104775 Recruiting - Clinical trials for Hematologic Malignancies

A Study of GNC-035, a Tetra-specific Antibody, in Participants With Relapsed/Refractory Hematologic Malignancy

Start date: February 9, 2022
Phase: Phase 1
Study type: Interventional

In this study, the safety, tolerability and preliminary effectiveness of GNC-035 in patients with relapsed/refractory hematologic malignancies will be investigated to assess the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) or maximum administered dose (MAD) for MTD is not reached of GNC-035.

NCT ID: NCT05028478 Not yet recruiting - Clinical trials for Hematologic Malignancies

A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies

Start date: October 22, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The study is designed to evaluate the safety, tolerability, pharmacokinetic characteristics and anti-tumor activity of CN202 in adult subjects with locally advanced or metastatic solid tumor or hematologic malignancies

NCT ID: NCT04758442 Recruiting - Clinical trials for Hematologic Malignancies

Optimal Dosing of Vancomycin in an Adult Population of Hemato-oncology

Hemato-Vanco
Start date: February 1, 2021
Phase: N/A
Study type: Interventional

This is a single-center prospective pharmacokinetic study. The principal objective is to collect new data among patients with hematologic cancer to develop a Bayesian population pharmacokinetic model and to improve dose adjustment of intravenous vancomycin. Approximately 40 subjects meeting the inclusion and no exclusion criteria will be enrolled in the study. Vancomycin blood concentration will be measured at steady-state at three different moment for each participant : immediately before the infusion, 1 hour after the infusion and during the elimination phase (at 3, 4 or 5 hours after the infusion). This additional vancomycin serum concentration in the elimination phase will be used to estimate more precisely the vancomycin pharmacokinetic parameters in this specific population including the distribution volume and the elimination of the molecule. Ultimately, the purpose of this study is to create a nomogram to predict the optimal initial vancomycin dosing in adult patients with a hematologic cancer.

NCT ID: NCT04728893 Recruiting - Clinical trials for Hematologic Malignancies

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

Start date: April 5, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of nemtabrutinib (formerly ARQ 531) in participants with hematologic malignancies of chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), Richter's transformation, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and Waldenström's macroglobulinemia (WM).

NCT ID: NCT04696809 Active, not recruiting - Clinical trials for Hematologic Malignancies

A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma

Start date: February 22, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of the study is to evaluate the safety and tolerability in Japanese participants with relapsed or refractory multiple myeloma (RRMM) at the recommended Phase 2 dose (RP2D) identified in Study 64007957MMY1001 (NCT03145181) in Phase 1 part and to evaluate the efficacy of teclistamab at RP2D for Japanese participants in Phase 2 part.

NCT ID: NCT04588922 Recruiting - Clinical trials for Hematologic Malignancies

A Study of GFH009 in Patients With Hematologic Malignancies

Start date: May 10, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

GFH009 is a potent and highly selective CDK9 inhibitor. To assess the safety, tolerability, and antitumor activity of single agent GFH009, this study consists of two dose escalation groups in patients with relapsed/refractory acute myeloid leukemia (Group 1) and in patients with relapsed/refractory lymphomas (Group 2). The safety, tolerability, and antitumor activity of GFH009 in combination with venetoclax and azacitidine in patients with relapsed/refractory acute myeloid leukemia (AML) who have relapsed on or are refractory to venetoclax-based regimens will also be assessed (Group 3).

NCT ID: NCT04581187 Recruiting - Clinical trials for Hematologic Malignancies

An Online-platform to Improve Patient-centered Care During the COVID-19 Pandemic: a GIMEMA Surveillance Program in Hematologic Malignancies

Start date: December 2, 2020
Phase:
Study type: Observational [Patient Registry]

This is a national multicenter prospective observational study led by the GIMEMA. The GIMEMA-ALLIANCE Platform is also an online monitoring system for patients with hematologic malignancies aiming at helping hematologists in the early recognition and timely management of problems of their patients. Based on patient's rating of specific items (i.e. on the presence of clinically relevant problems or problems with adherence to therapy or risk of SARS-CoV-2 infection), the Platform will automatically send alerts to the treating hematologist (and/or appointed members of the local Team). Physicians will be free to make any action they feel appropriate for the best care of their patients.

NCT ID: NCT04546945 Recruiting - Clinical trials for Hematologic Malignancies

Aberrant Expression of CD56 in Patients With Hematologic Malignancies.

Start date: July 20, 2020
Phase:
Study type: Observational [Patient Registry]

CD56(cluster of differentiation 56) was found to be ectopically expressed in multiple myeloma . A met analysis indicated that CD56 over expression may be an adverse prognostic factor in AML. To the best of our knowledge, no available data the expression pattern of CD56 in other Hematologic malignancies. This work is designed to evaluate the expression pattern of CD56 in hematologic malignancies.

NCT ID: NCT04538599 Completed - Clinical trials for Hematologic Malignancies

RD13-01 for Patients With r/r CD7+ T/NK Cell Hematologic Malignancies

Start date: September 10, 2020
Phase: Phase 1
Study type: Interventional

This study is designed to explore the safety of RD13-01 for patients with CD7+ relapsed and/or refractory T/NK-cell hematologic malignancies. And to evaluate the efficacy and pharmacokinetics of RD13-01 in patients.

NCT ID: NCT04478916 Recruiting - Solid Tumor Clinical Trials

Impact of the Comprehensive Geriatric Assessment on the Quality of Life OF Elderly Patients

ONCO-AGING
Start date: December 18, 2019
Phase:
Study type: Observational

Impact of the Comprehensive Geriatric Assessment on the Quality of Life of elderly onco-hematologic patients' candidates for complex antitumoral therapies: clinical and biological correlatives